Prostate Cancer Coverage from Every Angle

Amir Goldkorn, MD, on Challenges of Integrating a Prostate Cancer Prognostic Marker Into Standard Practice

Posted: Tuesday, June 9, 2020

Amir Goldkorn, MD, of USC Norris Comprehensive Cancer Center, discusses findings from SWOG S1216, which showed that using circulating tumor cell (CTC) count at the start of treatment for metastatic castration-sensitive prostate cancer was prognostic of 7-month PSA response and progression-free survival at 2 years. He also discusses the possible challenges of integrating CTC count into standard practice.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.